Lysyl Oxidase Dynamics in Cancer Metastasis

Lysyl oxidases constitute an extracellular family of copper‐dependent amine oxidases that catalyse covalent cross‐linking of collagen and elastin, thereby modulating the mechanical properties of the extracellular matrix. In many solid tumours, dysregulated lysyl oxidase activity drives a cascade of matrix remodelling events that foster tumour cell invasion, intravasation and the establishment of distant metastases. Through stiffening of the tumour stroma and formation of a pre‐metastatic niche, lysyl oxidases promote angiogenesis, immune cell recruitment and chemoresistance. Their expression is often induced by hypoxia and orchestrated by transcription factors such as HIF-1α, linking tumour microenvironmental cues to enhanced metastatic competence. The emerging paradigm positions lysyl oxidases as both biomarkers of aggressive disease and therapeutic targets to impede metastatic progression and potentiate cytotoxic treatments.

Research from Nature Portfolio

Recent studies have advanced first‐in‐class pan-lysyl oxidase inhibitors that attenuate tumour desmoplasia and metastasis. A highly selective small molecule has been shown in preclinical pancreatic cancer models to reduce collagen cross-linking, decrease tissue stiffness and diminish metastatic spread, while synergising with standard chemotherapy to improve survival. Parallel work in triple-negative breast cancer has demonstrated that inhibiting lysyl oxidase alleviates hypoxia-induced extracellular matrix remodelling, restores drug penetration by reducing collagen and fibronectin assembly, and re-sensitises resistant tumours to cytotoxic agents. These findings collectively validate lysyl oxidase inhibition as a dual strategy to remodel the tumour microenvironment and overcome chemoresistance.

Lysyl Oxidase Dynamics in Cancer Metastasis publication trend

The graph below shows the total number of articles in lysyl oxidase dynamics in cancer metastasis across all publications each year (not limited to Nature Index journals).

Technical terms

Lysyl oxidase (LOX): copper‐dependent enzyme catalysing collagen and elastin cross-linking in the extracellular matrix.

Extracellular matrix (ECM): complex network of proteins and glycans that provides structural integrity and biochemical signals to cells.

Desmoplasia: fibrotic tissue response characterised by excessive collagen deposition and increased matrix stiffness around tumours.

Epithelial–mesenchymal transition (EMT): biological programme through which epithelial cells acquire motility and invasive capacity.

Pre-metastatic niche: primed microenvironment in secondary organs that supports survival and colonisation of disseminated tumour cells.

Chemoresistance: capacity of cancer cells to evade the cytotoxic effects of chemotherapy agents.

References

1. Lysyl Oxidase and the Tumor Microenvironment. International Journal of Molecular Sciences (2016).
2. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Nature Cancer (2023).
3. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nature Communications (2020).
4. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine (2015).
5. Lysyl oxidase‐like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal‐like breast carcinomas. EMBO Molecular Medicine (2011).